Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. (scientific article published on 9 January 2018)

Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin

Q24533183

Non-invasive diagnosis of liver fibrosis and cirrhosis

Q26778033

Ultrasound-based elastography for the diagnosis of portal hypertension in cirrhotics

Q26778038

Natural history of hepatitis C

Q27000737

Hepatic steatosis and fibrosis: Non-invasive assessment.

Q28077200

Functional studies on recombinant domains of Mac-2-binding protein

Q28203993

Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin

Q28307905

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

Q29614898

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Q29614930

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

Q29616215

Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.

Q30364476

Shear wave elastography in hepatitis C patients before and after antiviral therapy.

Q30365483

Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus

Q30375738

Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients.

Q30422199

A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis

Q30459124

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

Q30892564

Hepatic stellate cells secreting WFA+ -M2BP: Its role in biological interactions with Kupffer cells.

Q51240926

Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.

Q51678128

Regulation of RAW264.7 macrophage polarization on smooth and rough surface topographies by galectin-3.

Q52652369

Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis.

Q53096048

Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C.

Q53123382

FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

Q62658359

New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver

Q83291235

Liver biopsy

Q83395480

Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease

Q85822195

Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis

Q86266602

Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-γ-inducible protein-10 in primary biliary cirrhosis

Q86311356

Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis

Q86488395

Clinical implication of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level on hepatitis B e-antigen loss or seroconversion in hepatitis B e-antigen positive patients

Q87116182

Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis

Q87210614

Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naïve chronic hepatitis B

Q87486839

Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers

Q87503213

Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.

Q33643388

Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.

Q33655116

Liver cirrhosis

Q34010340

Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis

Q34216210

A systematic review of the quality of liver biopsy specimens

Q34527432

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Q34544284

Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.

Q35662485

Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease.

Q36331900

Grading and staging systems for inflammation and fibrosis in chronic liver diseases

Q36907971

A starring role for stellate cells in the pancreatic cancer microenvironment

Q37059888

A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation

Q37226309

Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus

Q37286603

Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein

Q37534952

Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis

Q37676132

Assessment of fibrosis and cirrhosis in liver biopsies: an update

Q37846151

Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy

Q38460386

Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics

Q38591154

Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression

Q38742635

Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma

Q38743976

Gluten-induced cognitive impairment ("brain fog") in coeliac disease

Q39154331

Usefulness of Mac-2 Binding Protein Glycosylation Isomer for Prediction of Posthepatectomy Liver Failure in Patients With Hepatocellular Carcinoma

Q39646258

M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection.

Q40185673

Serum WFA(+) -M2BP levels predict liver fibrosis, development of hepatocellular carcinoma, and overall survival: A meta-analysis

Q40244120

Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.

Q40343824

Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy

Q40513639

Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis

Q40582320

Serum WFA+ -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection.

Q40701776

Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

Q40735572

Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection

Q40776645

Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients

Q40907796

Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.

Q40936469

Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis

Q41009473

Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma

Q41215811

Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment

Q41471144

Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients

Q41624343

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study

Q42049084

A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis.

Q42233241

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

Q42999261

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease

Q44244167

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Q44527614

Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling

Q45115313

Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastography

Q46547124

Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development.

Q48155717

Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury

Q48183214

Serum levels of Wisteria floribunda agglutinin-positive Mac-2 binding protein reflect the severity of chronic pancreatitis.

Q51049727

P433

issue

P921

main subject

biomarker

Q864574

P304

page(s)

819-826

P577

publication date

2018-01-09

P1433

published in

Journal of Gastroenterology

Q15764399

P1476

title

Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis

P478

volume

Reverse relations

cites work (P2860)

Q58566001	Advanced assessment of serum Mac-2 binding protein glycosylation isomer in patients with biliary atresia
Q101133429	Aglycosylated antibody-producing mice for aglycosylated antibody-lectin coupled immunoassay for the quantification of tumor markers (ALIQUAT)
Q94603199	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
Q55324101	Biomarkers for primary biliary cholangitis: current perspectives.
Q92088888	Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis
Q90245775	Elevation of Mac-2 binding protein glycosylation isomer after hepatectomy is associated with post-hepatectomy liver failure, total Pringle time, and renal dysfunction
Q88431630	Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease
Q90073141	Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases
Q92978996	Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis
Q57493366	Gd-EOB-DTPA DCE-MRI biomarkers in a rabbit model of liver fibrosis
Q55347868	Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis.
Q97093731	Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling
Q89551187	Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi
Q90593073	Oral administration of eicosapentaenoic acid suppresses liver fibrosis in postoperative patients with biliary atresia
Q92972947	Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation: its implication of posttransplant small-for-size syndrome
Q58565993	Response to the letter by Dr. Naoya Yamada, and Dr. Koichi Mizuta regarding our manuscript: "Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis"
Q93080566	Significant Correlation Between Grip Strength and m2bpgi in Patients with Chronic Liver Diseases
Q96816149	Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis

P356	DOI	10.1007/S00535-017-1425-Z
P698	PubMed publication ID	29318378